|
|
|
|
Anti-TCF7L1 / TCF-3 Antibody (aa429-581) LS-C132609
Most Popular TCF7L1 / TCF-3 Antibodies
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|
|
Details
| Human TCF7L1 / TCF-3 | |
| Sheep | |
| Human (tested or 100% immunogen sequence identity) | |
| IgG Polyclonal | |
| Unconjugated | |
| Immunoaffinity purified | |
| Unmodified |
Applications
| Western blot (0.2 µg/ml) |
Specificity and Use
| TCF7L1 / TCF-3 antibody was raised against e. coli-derived recombinant human TCF7L1 (rhTCF7L1; aa429-581; Accession # Q9HCS4). | |
| aa429-581 | |
| Recognizes human TCF7L1. | |
| Suitable for use in Western blot: 0.2 ug/ml. |
Packaging
| Lyophilized from PBS, 5% trehalose | |
| PBS, 0.02% sodium azide. | |
| Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. | |
| For research use only. |
About TCF7L1 / TCF-3
Q9HCS4
NM_031283
NP_112573.1
TCF7L1 Antibody, TCF-3 Antibody, Transcription factor 7-like 1 Antibody, HMG box transcription factor 3 Antibody
Participates in the Wnt signaling pathway. Binds to DNA and acts as a repressor in the absence of CTNNB1, and as an activator in its presence. Necessary for the terminal differentiation of epidermal cells, the formation of keratohyalin granules and the development of the barrier function of the epidermis (By similarity). Down-regulates NQO1, leading to increased mitomycin c resistance.
Print This Page
Technical Help
Review This Product
Requested From:
Date Requested: 4/19/2018
Date Requested: 4/19/2018
